Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges.
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges.
复制标题
DOI：
10.1158/2159-8290.cd-11-0110
复制
发表时间：
2011-09
期刊：
影响因子：
28.2
通讯作者：
Hahn WC
中科院分区：
文献类型：
--
作者：
MacConaill LE;Van Hummelen P;Meyerson M;Hahn WC
越来越多的抗癌治疗剂针对许多不同肿瘤类型表达的特定突变蛋白。最近的证据表明，选择肿瘤具有特定基因改变的患者可以确定最有可能从使用此类药物中受益的患者子集。随着提供诊断和/或治疗信息的基因改变数量的增加，癌症基因组的全面表征对于了解癌症中不同基因组改变的范围、识别可能对特定疗法有反应的患者以及促进治疗方式的选择是必要的。基因组分析新技术的快速发展现在提供了对癌症基因组进行全面分析的手段。在这里，我们回顾了癌症基因组分析的现状，并讨论了在临床环境中实施这些技术所需的挑战和机遇。
An increasing number of anti-cancer therapeutic agents target specific mutant proteins that are expressed by many different tumor types. Recent evidence suggests that the selection of patients whose tumors harbor specific genetic alterations identifies the subset of patients that are most likely to benefit from the use of such agents. As the number of genetic alterations that provide diagnostic and/or therapeutic information increases, the comprehensive characterization of cancer genomes will be necessary to understand the spectrum of distinct genomic alterations in cancer, to identify patients who are likely to respond to particular therapies and to facilitate the selection of treatment modalities. Rapid developments in new technologies for genomic analysis now provide the means to perform comprehensive analyses of cancer genomes. Here we review the current state of cancer genome analysis and discuss the challenges and opportunities necessary to implement these technologies in a clinical setting.